Eson Ekpo, M.D.

Proud to share our new @American_Heart Scientific Statement in Circulation. Up to 60% of hospitalized CV patients are affected. Early recognition + nutrition support matter. 🫀#Cardiology #HeartFailure #CardioTwitt ahajournals.org/doi/full/10.11…

In Chicago and had to visit my mentors from medical school. Happy to see my artwork is still hanging up in the study lounge.#UICCOM #UIC

The struggles of pulling off a manuscript in the middle of a busy AHF fellowship.

Excited to be presenting at this year’s Urban Medicine Policy and Advocacy Forum. I am proud of the work my medical school does and the medical students who are committed to partnering with local organizations to address health disparities through service learning and advocacy.

Had an integrative medicine question on my HF practice questions today😁

When ADHD & dyslexia are not excuses for failure, so I create 18-month structured schedules to study for boards. I later learned that this is called an individualized learning plan and is often used for students who are neurodivergent. Where were ILRs when I was in school?

Taking some time to put on my preventative cardiology hat… Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank | European Journal of Preventive Cardiology | Oxford Academic academic.oup.com/eurjpc/advance…

Determined to understand this thing we call Transplant Cardiology; but why does every other paragraph say there’s not enough evidence to recommend…. If the experts don’t know, how am I supposed to know #AHFTC

I was crazy enough to join a busy Integrative Medicine Fellowship in the middle of my cardiology training, but I am glad I did. It was worth it.! One more fellowship to go. #IntegrativeMedicine #IntegrativeCardiology #AIHM

👀 @Stanford_HF surpassed 2⃣5⃣0⃣0⃣🫀transplants in program history this month‼️ Congratulations to the entire team that makes this possible 🙌🎆🥳 @Stanford @stanfordctsurg @StanfordMed @StanCVFellows @StanfordCVI @ISHLT @HFSA @tcccop @KiranKhush1 @EldrinL @Erik_Henricksen

(10/10) HELIOS-B shows RNAi therapy can significantly improve survival and HF outcomes in ATTR-CM. Vutrisiran’s success establishes TTR gene silencing as a viable strategy alongside stabilizers, heralding a new era for #Amyloidosis care. #CardioTwitter #JACC

(9/10) #Vutrisiran (SC q3mo) is poised to join tafamidis as a therapy for ATTR-CM. Its q3-month dosing is more convenient than patisiran (IV q3w). A silencer + stabilizer combination might offer added benefit, but needs confirmation in future trials. #Amyloidosis

(1/10) 🧬Vutrisiran, a subcutaneous RNAi therapy, significantly reduces all-cause mortality & CV events in the HELIOS-B trial - benefits seen even with background tafamidis. #CardioTwitter #ATTR #HeartFailure #RNAi #JACC jacc.org/doi/10.1016/j.…